A panel of experts explore the clinical and economic burden of vitiligo, review treatment paradigms and standard of care therapies, and discuss unmet needs and future directions for treatment of vitiligo.
EP. 1: Illustrating the Presentation of Vitiligo
A panel of experts open a discussion surrounding vitiligo, including the definition and nature of the disease.
EP. 2: Prevalence of Vitiligo Across Patient Demographics
David Rosmarin, MD, discusses the prevalence and incidence of vitiligo across a diverse patient population.
EP. 3: Clinical Burden Associated with Vitiligo
Vitiligo’s effects on clinical burden and patient quality of life are addressed by Brett King, MD, PhD, and David Rosmarin, MD.
EP. 4: Payer Considerations Unique to Vitiligo Treatment
David Epstein, MD, MBA, an independent consultant, gives an overview of payer considerations surrounding vitiligo.
EP. 5: Comorbidities Associated with Vitiligo
Comorbidities and disease states associated with vitiligo are explored by a panel of key opinion leaders.
EP. 6: Frontline Therapies for Vitiligo Treatment
Dr Dunn leads a discussion outlining frontline therapies for the treatment of vitiligo.
EP. 7: Economic Burden Surrounding Vitiligo
The panel of experts address the economic burden of vitiligo from payer and provider perspectives.
EP. 8: Vitiligo Diagnosis Determining Treatment Pathways
Key opinion leaders discuss how diagnosing vitiligo can lead to myriad treatment options.
EP. 9: Optimal Therapies for Treating Vitiligo
A variety of treatment options for vitiligo are explored by Drs Dunn, Rosmarin, and King.
EP. 10: Aligning Payer and Provider Considerations
Navigating payer and provider considerations to ensure optimal care management for vitiligo.
EP. 11: Unmet Needs in Vitiligo Treatment Landscape
The panel navigates unmet needs surrounding the vitiligo treatment landscape.
EP. 12: Role of JAK Inhibitors in Treatment of Vitiligo
Dr Rosmarin illustrates treatment management of vitiligo with the use of JAK inhibitors.
EP. 13: Safety Considerations for Vitiligo-Focused Drug Therapies
Safety considerations, particularly surrounding JAK inhibitors in vitiligo treatment, are emphasized by the panelists.
EP. 14: Non-JAK Inhibitor Therapy Options Available for Vitiligo Treatment
Dr King presents interleukin-15, a non-JAK inhibitor therapy option for the treatment of vitiligo.
EP. 15: Payer Support for Emerging Vitiligo Treatments
The panel discusses emerging treatments for vitiligo and addresses opportunities for payers to support implementation.
EP. 16: Trajectory of Vitiligo Treatment Landscape
Experts provide closing pearls regarding the current and prospective treatment landscape of vitiligo.
2 Clarke Drive Cranbury, NJ 08512